brand of product where (NBA) of product brands supply constraints allow. within hospitals which may be difficult to (Prescriber, Nurse, manage without this Dispenser, Authoriser, flag. NBA) Date Date Time The date of the Must not be The date of the most Display of previous Failure to collect/display Use Transparent to – previous current or recent treatment is treatment will avoid the date of previous some of system treatment future date. important to schedule duplicate treatments treatment will result in (see security matrix). the next treatment. being scheduled and paper records needing No disclosure other given. Data analysis of to be accessed and (Prescriber, Nurse, than at level of treatment timings is an reduces the efficiency of Dispenser, Authoriser, aggregated important indicator to the system to support Ig NBA) reports for clinical support evaluation of treatment. Risk of governance and Ig treatment effectiveness duplicate treatments at governance purposes. and Ig performance incorrect time intervals management. being given across different sites. (Hospital, NBA) Response Text A comment on The recording of the Failure to collect and Use Transparent to – the patient’s response patients have display the patient’s some users of system response to the had to particular brands response to a previous (see security matrix). treatment. of Ig product ensures Ig treatment may result No disclosure than that allocation of the in patients receiving a at level of de-identified next treatment type is brand of product to aggregated reports for appropriate for patient which they have had a clinical governance and safety. reaction.
brand of product where supply constraints allow. (Prescriber, Nurse, Dispenser, Authoriser, NBA) (NBA) of product brands within hospitals which may be difficult to manage without this flag. Date Date Time The date of the previous treatment Must not be current or future date. The date of the most recent treatment is important to schedule the next treatment. (Prescriber, Nurse, Dispenser, Authoriser, NBA) Display of previous treatment will avoid duplicate treatments being scheduled and given. Data analysis of treatment timings is an important indicator to support evaluation of treatment effectiveness and Ig performance management. (Hospital, NBA) Failure to collect/display the date of previous treatment will result in paper records needing to be accessed and reduces the efficiency of the system to support Ig treatment. Risk of duplicate treatments at incorrect time intervals being given across different sites. Use – Transparent to some of system (see security matrix). No disclosure other than at level of aggregated reports for clinical governance and Ig governance purposes. Response Text A comment on the patient’s response to the treatment. The recording of the response patients have had to particular brands of Ig product ensures that allocation of the next treatment type is appropriate for patient safety. Failure to collect and display the patient’s response to a previous Ig treatment may result in patients receiving a brand of product to which they have had a reaction. Use – Transparent to some users of system (see security matrix). No disclosure than at level of de-identified aggregated reports for clinical governance and
ig-gov-and-system-privacy-impact-assesmt-rprt.DOCX